利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

94 条记录 (耗时 0.042 秒)

    Inhibition of Glycogen Synthase Kinase and Methods of Treating Autoimmune or Immune Inflammatory Disease
    2.
    发明申请
    Inhibition of Glycogen Synthase Kinase and Methods of Treating Autoimmune or Immune Inflammatory Disease 审中-公开
    抑制糖原合酶激酶和治疗自身免疫性或免疫性炎性疾病的方法

    公开(公告)号：US20090306045A1

    公开(公告)日：2009-12-10

    申请号：US11991654

    申请日：2006-12-22

    申请人： Ira Mellman ,  Aimin Jiang

    发明人： Ira Mellman ,  Aimin Jiang

    IPC分类号： A61K31/55 ,  A61K31/4015 ,  A61P37/00

    CPC分类号： A61K31/4745 ,  A61K31/503

    摘要： The present invention relates to the use of glycogen synthase kinase 3(GSK3) inhibitors, especially inhibitors of GSK-3α, GSK-3β and GSK-3β2, preferably, inhibitors of GSK-3β, in patients having autoimmune diseases and/or immune dysfunction/dysregulation to induce immune tolerance. Inhibition of GSK leads to activation of a pathway of dendritic cell maturation which leads to a dendritic phenotype which attenuates, rather than induces, immune responses. The immune responses and mature dendritic cells produced by the method of the present invention redirect or attenuate the immune response in individuals, thus leading to effective therapies for a number of autoimmune diseases and/or diseases of immune dysfunction/dysregulation (immune inflammatory diseases), including systemic lupus erythematosus (SLE), autoimmune diabetes (type I diabetes mellitus), asthma, rheumatoid arthritis, inflammatory bowel disease, among numerous others.

    摘要翻译： 本发明涉及在具有自身免疫性疾病和/或免疫功能障碍的患者中使用糖原合酶激酶3（GSK3）抑制剂，特别是GSK-3α，GSK-3β和GSK-3β2抑制剂，优选GSK-3β抑制剂 /失调诱导免疫耐受。 GSK的抑制导致树突细胞成熟途径的激活，这导致树突状表型减弱而不是诱导免疫应答。 通过本发明的方法产生的免疫应答和成熟树突状细胞改变或减弱个体的免疫应答，从而导致许多自身免疫疾病和/或免疫功能障碍/失调（免疫炎性疾病）疾病的有效治疗， 包括系统性红斑狼疮（SLE），自身免疫性糖尿病（I型糖尿病），哮喘，类风湿性关节炎，炎性肠病等。

    Pyrrolo[1,2b]pyridazine compounds and their uses
    7.
    发明申请
    Pyrrolo[1,2b]pyridazine compounds and their uses 审中-公开
    吡咯并[1,2b]哒嗪化合物及其用途

    公开(公告)号：US20060148807A1

    公开(公告)日：2006-07-06

    申请号：US11378537

    申请日：2006-03-17

    申请人： Jian-min Fu

    发明人： Jian-min Fu

    IPC分类号： A61K31/503 ,  G01N33/53

    CPC分类号： A61K31/503 ,  G01N33/566 ,  G01N2500/00

    摘要： Disclosed are novel CRF receptor antagonists and their use as treatment of a variety of disorders, including disorders manifesting hypersecretion of CRF or associated with CRF or CRF receptors, such as anxiety, and depression. CRF receptor antagonists of the invention have the structure of formula (I): including stereoisomers or mixture of stereoisomers, pharmaceutically acceptable prodrugs, or pharmaceutically acceptable salts thereof, wherein in formula (I) R is H or Me.

    摘要翻译： 公开了新的CRF受体拮抗剂及其用于治疗多种疾病的用途，包括表现出CRF过度分泌或与CRF或CRF受体如焦虑和抑郁症相关的疾病。 本发明的CRF受体拮抗剂具有式（I）的结构：包括立体异构体或立体异构体的混合物，药学上可接受的前药或其药学上可接受的盐，其中在式（I）中R是H或Me。